BioPharmSignal logoBioPharmSignal

Biotech News

LIXTE Biotechnology Holdings Highlights Q4 2025 Priorities, Including Ongoing Advancement of Lead Candidate LB-100, Strategic Oncology Business Development and Acquisition Plans

Lixte Biotechnology Holdings (LIXT)Lixte Biotechnology HoldingsCompany update

LIXT (LIXT) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is lixt.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

LIXTLixte Biotechnology Holdings2026-06-18 12:30 EST

LIXTE Biotechnology Provides Update on NOMAD Acquisition; Transaction Expected to Close On or About July 1, 2026

LIXTLixte Biotechnology Holdings2026-06-12 12:30 EST

LIXTE Biotechnology to Acquire NOMAD Transportable Power Systems, the Market Leader in Mobile, Utility-Grade Battery Energy Storage Systems (BESS)

LYELLyell Immunopharma2026-08-06 20:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026

RVMDRevolution Medicines2026-08-10 10:01 EST

Revolution Medicines and BeOne Medicines Announce Clinical Development and Regional Commercialization Collaboration

BMEABiomea Fusion2026-08-05 20:05 EST

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

ERASErasca2026-07-13 20:01 EST

Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors

BNTXBioNTech2026-08-20 09:30 EST

BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026

LEGNLegend Biotech Corporation2026-08-11 11:00 EST

Legend Biotech Reports Second Quarter 2026 Results and Recent Highlights

COGTCogent Biosciences2026-08-10 12:00 EST

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results

GERNGeron2026-08-05 11:00 EST

Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights

View all latest news

Lixte Biotechnology Holdings

PP2A Inhibition in Cancer LIXTE Biotechnology develops cancer therapies based on inhibition of protein phosphatase 2A. Its lead molecule is intended to sensitize tumors to chemotherapy and immunotherapy rather than function solely as a stand-alone cytotoxic drug. LB-100 LB-100 is a first-in-class clinical PP2A inhibitor that has shown...

Recent company news

LIXTLixte Biotechnology Holdings2026-08-19 12:30 EST

NOMAD Achieves UL 9540 Certification for 1 MW Transportable Battery Energy Storage System

LIXTLixte Biotechnology Holdings2026-08-14 12:35 EST

NOMAD POWER SOLUTIONS FILES 2026 SECOND QUARTER FORM 10-Q, PROVIDES BUSINESS UPDATE

LIXTLixte Biotechnology Holdings2026-07-31 12:30 EST

NOMAD Power Solutions Announces Options Trading Begins on Cboe Options Exchange

LIXTLixte Biotechnology Holdings2026-07-29 12:30 EST

NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative

LIXTLixte Biotechnology Holdings2026-07-15 12:30 EST

NOMAD Power Solutions Strengthens Subsidiary Executive Leadership

Stock data

Close
7.21 USD
Market cap
87.18M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States